Fundamentals for AstraZeneca Pharma India Limited

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Revenue projections:

Financial Ratios:

currentRatio	1.77200
forwardPE	0.00000
debtToEquity	12.67900
earningsGrowth	-0.23000
revenueGrowth	0.20400
grossMargins	0.39332
operatingMargins	0.09559
trailingEps	75.07000
forwardEps	0.00000

The current ratio for ASTRAZEN is 1.772, indicating that the company can service its short-term debt using available cash and assets. This suggests ASTRAZEN has strong liquidity, with more than enough resources to meet its immediate financial commitments.
AstraZeneca Pharma India Limited's low Debt-to-Equity ratio suggests the company is minimally leveraged, with limited reliance on debt to finance its operations. This reduced financial risk positions the company for greater stability and financial health, appealing to investors who value conservative financial management.
With both earnings and revenue growth in low territory, ASTRAZEN is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
AstraZeneca Pharma India Limited's negative gross and operating margins suggest that the company is currently facing financial difficulties, as it is unable to cover production and operational costs. This could result in significant losses if not addressed.